戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  and 124 respondents (14.9%) had ever used a sedative-hypnotic.
2 e serotonin reuptake inhibitors) and 27.4% a sedative/hypnotic.
3  for severe anxiety that was unresponsive to sedative hypnotics.
4 it mediate sedation and serve as targets for sedative hypnotics.
5 novel aspects of neurobiological response to sedative-hypnotics.
6 e sedation and need for constant infusion of sedative-hypnotics.
7 ntly increasing the use of antipsychotics or sedative-hypnotics.
8 nstitute the majority of clinically relevant sedative-hypnotics.
9 sants (13 of 16), antipsychotics (10 of 12), sedative-hypnotics (6 of 10), and stimulants (6 of 10).
10                Etomidate is a nonbarbiturate sedative hypnotic agent with no analgesic properties.
11                           Propofol is also a sedative hypnotic agent with rapid onset and short durat
12 e of anesthesiology are employing new potent sedative hypnotic agents to accomplish effective pediatr
13 al uses as anticonvulsants, anxiolytics, and sedative-hypnotic agents.
14 ion and have been implicated in responses to sedative/hypnotic agents (including neuroactive steroids
15 ious studies have shown that a wide range of sedative/hypnotic agents, including ethanol, induce slee
16 -4(3H)-quinazolinone, Quaalude), an infamous sedative-hypnotic and recreational drug from the 1960s-1
17 in a wide variety of behavioral responses to sedative-hypnotics and may directly facilitate progress
18                                   Anxiolytic/sedative/hypnotic and antidepressant medication use were
19 zodiazepines, which are often used for their sedative/hypnotic and anxiolytic effects.
20  of clinical agents, including anaesthetics, sedatives, hypnotics and antidepressants(1-3).
21        Particularly addressing the fields of sedatives, hypnotics and neuromuscular blockers, however
22 he target of a structurally diverse group of sedative, hypnotic, and anesthetic drugs, including the
23  currents and to test their contributions to sedative, hypnotic, and immobilizing anesthetic actions.
24                   Daily doses of all opioid, sedative, hypnotic, and major tranquilizer drugs adminis
25 r 2 or more antidepressants, antipsychotics, sedative-hypnotics, and antidepressant-antipsychotic com
26 r OUD, including cannabinoids, psychedelics, sedative-hypnotics, and immunotherapeutics, such as vacc
27 -risk medications, including antipsychotics, sedative-hypnotics, and strong anticholinergic agents.
28                          Chlormethiazole has sedative, hypnotic, anticonvulsant and neuroprotective p
29                                       Use of sedative-hypnotics before surgery is common, but its eff
30 lated by the anxiolytic, anticonvulsant, and sedative-hypnotic benzodiazepines.
31 justed RR, 1.87; 95% CI, 1.70-2.06), receive sedative hypnotics concurrently (40.7% vs 7.6%, adjusted
32           Propofol is the most commonly used sedative-hypnotic drug for noxious procedures, yet the m
33 uggest that dexmedetomidine could serve as a sedative-hypnotic drug to enhance clearance of harmful w
34 e identification and quantification of three sedative-hypnotic drugs namely diazepam, chlordiazepoxid
35 ency, while incidence of overdoses involving sedative/hypnotic drugs and psychotropic medications dec
36 n mice, but it should be applicable to other sedative/hypnotic drugs and to testing cerebellar mutant
37         However, we show that the ability of sedative/hypnotic drugs to enhance tonic inhibition in t
38 ptor numbers when considering the ability of sedative/hypnotic drugs to enhance tonic inhibition.
39 hanced by neurosteroids, antiepileptics, and sedative/hypnotic drugs.
40 tivating effects of low dose ethanol and the sedative-hypnotic effects of a high dose, while reduced
41 aling also altered the acute stimulatory and sedative-hypnotic effects of ethanol.
42 th neuronal development and tolerance to the sedative-hypnotic effects of GABA(A)R positive modulator
43 BA-gated channels, and thereby achieve their sedative-hypnotic effects.
44  could play a role in their immobilizing and sedative-hypnotic effects.
45             Behaviorally, the anxiolytic and sedative/hypnotic effects of alcohol are markedly reduce
46 eficient mice are also less sensitive to the sedative/hypnotic effects of ethanol, as shown by more r
47 o behavioral intoxication, as assayed by the sedative/hypnotic effects of ethanol.
48 ce for ethanol and are more sensitive to the sedative/hypnotic effects of this drug than controls.
49 iled to develop rapid tolerance to ethanol's sedative/hypnotic effects.
50 mplex traits, including diverse responses to sedative-hypnotics, have been detected on distal chromos
51 ntial toxicity from accentuated responses to sedative hypnotics in active cocaine-abusing subjects.
52 szopiclone (Lunesta(R)), a nonbenzodiazepine sedative hypnotic, increased N2 spindle density (number/
53 ombination with opioids, preoperative use of sedative-hypnotics increases the risk of adverse outcome
54 tential as anxiolytics, anticonvulsants, and sedative/hypnotics is limited by rapid metabolism.
55 dications to achieve tight glycemic control, sedative-hypnotic medications for insomnia or anxiety, a
56 odds ratio, 1.85; 95% CI, 1.06-3.24) but not sedative-hypnotic medications for insomnia or anxiety.
57  targeted for deprescribing (antipsychotics, sedative-hypnotics, or strong anticholinergics).
58                             Patients may use sedatives, hypnotics, or alcohol in an effort to interru
59 al ventilation (TV) and exposure to opioids, sedatives-hypnotics, or general anaesthetics in neonates
60           Antidepressant, antipsychotic, and sedative-hypnotic prescriptions were negatively associat
61 management of the surgical patient for their sedative/hypnotic properties although the alpha2 adrenoc
62 ht underlie the increased sensitivity to the sedative/hypnotic properties of ethanol but not the rewa
63 ether low doses, commonly used off-label for sedative-hypnotic purposes, are also associated with inc
64  and prolonged hypotensive, bradycardic, and sedative-hypnotic responses to alpha(2)AR stimulation.
65 f the delta subunit to GABA pharmacology and sedative/hypnotic responses and behavior and provide ins
66 y of 5 targeted medication classes (opioids, sedative-hypnotics, skeletal muscle relaxants, tricyclic
67                       The second described a sedative-hypnotic, such as zolpidem, being used for inso
68                                          For sedative-hypnotics, the phrase about side effects was 8.
69 tem depressant that was used clinically as a sedative-hypnotic, then became a notorious recreational
70  drug withdrawal events involving opioids or sedative-hypnotics were the main safety outcome.
71  visits in which neither antidepressants nor sedative/hypnotics were prescribed.
72 R, 15.46; 99% CI, 6.77-35.31); and 2 or more sedative-hypnotics, with anxiety disorders (OR, 2.13; 99
73 RK3 (Kir3.3), is associated with less severe sedative-hypnotic withdrawal.
74 ncy and often treated with nonbenzodiazepine sedative hypnotics (Z-drugs).
75 thdrawal from pentobarbital as well as other sedative-hypnotics (zolpidem and ethanol) versus wild-ty